2.72 (-%)
As of Nov 01, 2024
Source:
We are a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. We are developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patients use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients.
Country | United States |
Headquarters | south san francisco, california |
Phone Number | (650) 457-2700 |
Industry | manufacturing |
CEO | David Chang, M.D., Ph.D. |
Website | allogene.com |